PDCD1 and hepatocellular carcinoma: reported the safety and efficacy of augmenting PD-1 inhibitors to I-125 seed strand-stent, TACE, and lenvatinib in HCC with MPVTT, achieving a significantly prolonged median OS(17.7 months vs. 12.0 months, P = 0.01) (8).